The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis

Fan, Yu Pei; Hsia, Ching Chih; Tseng, Kuang Wen; Liao, Chih Kai; Fu, Tz Win; Ko, Tsui Ling; Chiu, Mei Miao; Shih, Yang Hsin; Huang, Pei Yu; Chiang, Yi Chia; Yang, Chi‐Rei; Fu, Yu

doi:10.5966/sctm.2015-0001

Cited by 38 publications

(34 citation statements)

References 74 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidences showed that HUMSCs exhibited long-term survival within different organs in rats and, therefore, could serve as an excellent cell source suitable for xenograft [39][40][41][42][43][44][45][46][47]. Experimental owchart for inducing PF in rats' left lung, administration of therapeutic agents nintedanib and pirfenidone, and transplantation of HUMSCs.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Reversal of Rat Pulmonary Fibrosis of Nintedanib, Pirfenidone and Human Umbilical Mesenchymal Stem Cells from Wharton’s Jelly

Chu

Yeh

Kuo³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background:The present study compared the effects of antifibrotic medications, pirfenidone and nintedanib, with transplantation of human umbilical mesenchymal stem cells (HUMSCs) in restoring rat pulmonary fibrosis (PF).Methods:A stable animal model was established via an intratracheal injection of 5 mg bleomycin (BLM). One single transplantation of 2.5 × 107 HUMSCs or initiation of daily oral nintedanib/pirfenidone administration was performed on Day 21 following BLM damage.Results:Pulmonary function examination revealed that BLM rats exhibited a significant decrease in blood oxygen saturation and an increase in respiratory rates. While no significant improvements were found in BLM rats receiving nintedanib or pirfenidone, those who transplanted with HUMSCs showed statistical amelioration in blood oxygen saturation and significant alleviation in respiratory rates. Quantification results revealed that a significant reduction in alveolar space and marked increases in substantial cell infiltration and collagen deposition in the left lungs of BLM rats. No significant alteration was observed in BLM rats administered nintedanib or pirfenidone. However, BLM rats transplanted with HUMSCs had a significant recovery in alveolar space and noticeable decreases in cell infiltration and collagen deposition. The inflammatory cell numbers in the bronchoalveolar lavage was increased in the BLM group. While the rats treated with nintedanib or pirfenidone had a lower cell number than the BLM group, a higher cell number was found as compared with the Normal group. In rats transplanted with HUMSCs, the cell number did not differ from the Normal group.Conclusions:Transplantation of HUMSCs could effectively treat PF as opposed to the administration of anti-fibrotic drugs with nintedanib or pirfenidone with significant better result in lung volume, pathological changes, lung function and blood oxygen saturation.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Reversal of Rat Pulmonary Fibrosis of Nintedanib, Pirfenidone and Human Umbilical Mesenchymal Stem Cells from Wharton’s Jelly

Chu

Yeh

Kuo³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Because the number of transplanted stem cells is considered as an important issue to regeneration, HUMSCs were implanted into different target-organs depending on the diseases [40][41][42][43][44][45][46][47][48]. In this study HUMSCs were implanted intratracheally to allow most transplanted stem cells migrating into damaged lung.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Reversal of Rat Pulmonary Fibrosis of Nintedanib, Pirfenidone and Human Umbilical Mesenchymal Stem Cells from Wharton’s Jelly

Chu

Yeh

Kuo³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background:The present study compared the effects of antifibrotic medications, Pirfenidone and Nintedanib, with transplantation of human umbilical mesenchymal stem cells (HUMSCs) in restoring rat pulmonary fibrosis (PF).Methods:A stable animal model was established via an intratracheal injection of 5 mg bleomycin (BLM). One single transplantation of 2.5 107 HUMSCs or initiation of daily oral Nintedanib/Pirfenidone administration was performed on Day 21 following BLM damage.Results:Pulmonary function examination revealed that BLM rats exhibited a significant decrease in blood oxygen saturation and an increase in respiratory rates. While no significant improvements were found in BLM rats receiving Nintedanib or Pirfenidone, those who transplanted with HUMSCs showed statistical amelioration in blood oxygen saturation and significant alleviation in respiratory rates. Quantification results revealed that a significant reduction in alveolar space and marked increases in substantial cell infiltration and collagen deposition in the left lungs of BLM rats. No significant alteration was observed in BLM rats administered Nintedanib or Pirfenidone. However, BLM rats transplanted with HUMSCs had a significant recovery in alveolar space and noticeable decreases in cell infiltration and collagen deposition. The inflammatory cell numbers in the bronchoalveolar lavage was increased in the BLM group. While the rats treated with Nintedanib or Pirfenidone had a lower cell number than the BLM group, a higher cell number was found as compared with the Normal group. In rats transplanted with HUMSCs, the cell number did not differ from the Normal group.Conclusions:Transplantation of HUMSCs could effectively treat PF as opposed to the administration of anti-fibrotic drugs with Nintedanib or Pirfenidone with significant better result in lung volume, pathological changes, lung function and blood oxygen saturation.

show abstract

“…Interestingly, several experimental studies have already demonstrated that intraperitoneally injection of MSCs is able to attenuate peritoneal inflammation and fibrosis in rodent models of peritoneal dialysis [42–44], indicating the possibility of using PD effluent-derived MSCs to reduce peritoneal membrane injury and fibrosis in PD patients.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stroma cells in peritoneal dialysis effluents from patients

Liu

Guan

et al. 2017

Human Cell

View full text Add to dashboard Cite

Mesenchymal stroma cells (MSCs) have potential as an emerging cell therapy for treating many different diseases, but discovery of the practical sources of MSCs is needed for the large-scale clinical application of this therapy. This study was to identify MSCs in peritoneal dialysis (PD) effluents that were discarded after PD. The effluents were collected from patients who were on the dialysis for less than 1 month. Adherent cells from the effluents were isolated by incubation in serum-containing medium in plastic culture dishes. Cell surface markers were determined by a flow cytometric analysis, and the in vitro differentiation to chondrocytes, osteocytes or adipocytes was confirmed by staining with a specific dye. After four passages, these isolated cells displayed the typical morphology of mesenchymal cells in traditional 2-D cultures, and were grown to form spherical colonies in 3-D collagen cultures. Flow cytometric analysis revealed that the unsorted cells from all of seven patient samples showed robust expression of typical mesenchymal marker CD29, CD44, CD73, CD90 and CD166, and the absence of CD34, CD79a, CD105, CD271, SSEA-4, Stro-1 and HLA-DR. In differentiation assays, these cells were induced in vitro to chondrocytes, osteocytes or adipocytes. In conclusion, this preliminary study suggests the presence of MSCs in the “discarded” PD effluents. Further characterization of the phenotypes of these MSCs and evaluation of their therapeutic potential, particularly for the prevention of PD failure, are needed.

show abstract

The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis

Cited by 38 publications

References 74 publications

Comparison of Reversal of Rat Pulmonary Fibrosis of Nintedanib, Pirfenidone and Human Umbilical Mesenchymal Stem Cells from Wharton’s Jelly

Comparison of Reversal of Rat Pulmonary Fibrosis of Nintedanib, Pirfenidone and Human Umbilical Mesenchymal Stem Cells from Wharton’s Jelly

Comparison of Reversal of Rat Pulmonary Fibrosis of Nintedanib, Pirfenidone and Human Umbilical Mesenchymal Stem Cells from Wharton’s Jelly

Mesenchymal stroma cells in peritoneal dialysis effluents from patients

Contact Info

Product

Resources

About